These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28956740)

  • 1. Genetic Correction and Hepatic Differentiation of Hemophilia B-specific Human Induced Pluripotent Stem Cells.
    He Q; Wang HH; Cheng T; Yuan WP; Ma YP; Jiang YP; Ren ZH
    Chin Med Sci J; 2017 Sep; 32(3):135-144. PubMed ID: 28956740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
    Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
    Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX.
    Ramaswamy S; Tonnu N; Menon T; Lewis BM; Green KT; Wampler D; Monahan PE; Verma IM
    Cell Rep; 2018 May; 23(5):1565-1580. PubMed ID: 29719266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
    Ma Y; Sun W; Zhao L; Yao M; Wu C; Su P; Yang L; Wang G
    Stem Cell Res Ther; 2022 Jul; 13(1):353. PubMed ID: 35883203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced cell-based modeling of the royal disease: characterization of the mutated F9 mRNA.
    Martorell L; Luce E; Vazquez JL; Richaud-Patin Y; Jimenez-Delgado S; Corrales I; Borras N; Casacuberta-Serra S; Weber A; Parra R; Altisent C; Follenzi A; Dubart-Kupperschmitt A; Raya A; Vidal F; Barquinero J
    J Thromb Haemost; 2017 Nov; 15(11):2188-2197. PubMed ID: 28834196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-step genetic correction of hemoglobin E/beta-thalassemia patient-derived iPSCs by the CRISPR/Cas9 system.
    Wattanapanitch M; Damkham N; Potirat P; Trakarnsanga K; Janan M; U-Pratya Y; Kheolamai P; Klincumhom N; Issaragrisil S
    Stem Cell Res Ther; 2018 Feb; 9(1):46. PubMed ID: 29482624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte-Like Cells Derived From Mouse Induced Pluripotent Stem Cells Produce Functional Coagulation Factor IX in a Hemophilia B Mouse Model.
    Wu YM; Huang YJ; Chen P; Hsu YC; Lin SW; Lai HS; Lee HS
    Cell Transplant; 2016; 25(7):1237-46. PubMed ID: 26395869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro recovery of FIX clotting activity as a marker of highly functional hepatocytes in a hemophilia B iPSC model.
    Luce E; Steichen C; Allouche M; Messina A; Heslan JM; Lambert T; Weber A; Nguyen TH; Christophe O; Dubart-Kupperschmitt A
    Hepatology; 2022 Apr; 75(4):866-880. PubMed ID: 34687060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
    Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
    Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation.
    Huang X; Wang Y; Yan W; Smith C; Ye Z; Wang J; Gao Y; Mendelsohn L; Cheng L
    Stem Cells; 2015 May; 33(5):1470-9. PubMed ID: 25702619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
    Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
    EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paired CRISPR/Cas9 Nickases Mediate Efficient Site-Specific Integration of
    Wang Y; Zhao J; Duan N; Liu W; Zhang Y; Zhou M; Hu Z; Feng M; Liu X; Wu L; Li Z; Liang D
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
    Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
    Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal Correction of Blood Coagulation Factor VIII in Patient-Derived Induced Pluripotent Stem Cells Using CRISPR/Cas9.
    Park CY; Sung JJ; Cho SR; Kim J; Kim DW
    Stem Cell Reports; 2019 Jun; 12(6):1242-1249. PubMed ID: 31105049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
    Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
    Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The State of Skewed X Chromosome Inactivation is Retained in the Induced Pluripotent Stem Cells from a Female with Hemophilia B.
    Lyu C; Shen J; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang D; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cells Dev; 2017 Jul; 26(13):1003-1011. PubMed ID: 28401797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Mediated In Situ Introduction or Integration of
    Tang Q; Hu Z; Zhao J; Zhou T; Tang S; Wang P; Xiao R; Chen Y; Wu L; Zhou M; Liang D
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells.
    Hiramoto T; Kashiwakura Y; Hayakawa M; Baatartsogt N; Kamoshita N; Abe T; Inaba H; Nishimasu H; Uosaki H; Hanazono Y; Nureki O; Ohmori T
    Commun Med (Lond); 2023 Apr; 3(1):56. PubMed ID: 37076593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.